Cover Image
市場調查報告書

白血球表面抗原 CD47:開發中產品分析

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 371021
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
白血球表面抗原 CD47:開發中產品分析 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2017
出版日期: 2017年06月20日 內容資訊: 英文 61 Pages
簡介

本報告提供以白血球表面抗原為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊CD47。

簡介

  • 調查範圍

白血球表面抗原 CD47 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aurigene Discovery Technologies Limited
  • Celgene Corporation
  • Trillium Therapeutics Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0871TDB

Summary

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 - Pipeline Review, H1 2017, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Non-Hodgkin Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Atherosclerosis, B-Cell Non-Hodgkin Lymphoma, Bacterial Infections, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Retinopathy, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Mycosis Fungoides, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Small-Cell Lung Cancer and T-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
  • The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
    • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
    • Aurigene Discovery Technologies Ltd
    • Celgene Corp
    • Forty Seven Inc
    • Surface Oncology Inc
    • Trillium Therapeutics Inc
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
    • ALX-148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-6H12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-90002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hu-5F9G4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PSTx-23 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CD47 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRF-231 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tigecycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTI-621 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTI-622 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade
      • May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting
      • Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
      • Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients
      • Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update
      • Mar 31, 2017: Aurigene to Present Data on CD47-SIRPI interaction program at the AACR 2017
      • Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621
      • Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial
      • Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-621
      • Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622
      • Jan 31, 2017: Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
      • Dec 15, 2016: Surface Oncology Appoints Robert Ross, MD as Chief Medical Officer
      • Dec 03, 2016: Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
      • Dec 02, 2016: Surface Oncology CD47 Program Demonstrates Promising Anti-Tumor Activity in Hematological Disease Models
      • Nov 29, 2016: Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Pipeline by Celgene Corp, H1 2017
  • Pipeline by Forty Seven Inc, H1 2017
  • Pipeline by Surface Oncology Inc, H1 2017
  • Pipeline by Trillium Therapeutics Inc, H1 2017
  • Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top